Medical food designs to enhance GLP-1 secretion in drug therapy
Innovative oral delivery system providing sustained release of incretin-stimulating postbiotic SCFAs, enhancing GLP-1 levels to support T2 diabetes control and weight loss. Aims to match the efficacy of gastric surgeries with non-invasive methods.
Overview
OneFul Health Inc. presents a groundbreaking approach to enhancing GLP-1 secretion through the development of medical food designs. By leveraging an oral delivery method, this solution offers sustained and targeted release of gram-level quantities of incretin-stimulating postbiotic short chain fatty acids (SCFAs) and micro-nutrients. This approach is designed to significantly increase GLP-1 levels, crucial for controlling Type 2 diabetes and achieving weight loss, potentially matching the efficacy of invasive gastric surgeries without the need for additional medications.
Technical specifications
Key features:
- Utilizes SCFAs and specific amino acids known to increase secretion of GLP-1 and PYY peptides.
- Provides a non-invasive alternative to increase endogenous GLP-1 levels, with potential effects similar to gastric bypass surgery.
- Focuses on sustained release in the distal intestines, directly supplying the necessary nutrients for optimal endocrine response.
- Proposed use of epithelial organoid experiments and observational trials to validate efficacy and optimize dosing.
Technology readiness level
This medical food design is at Technology Readiness Level 6, indicating that it has been tested in relevant environments and is approaching the stage of real-world application and validation through further trials and studies.
About OneFul Health Inc.
OneFul Health is an e-pharmacy for personalized combination therapies. It uses custom formulation software and patented pharmacy technology to deliver multi-drug prescriptions combined as a single pill or gel packet, with physician-approved formulations. The company positions its platform around multi-drug combination products (e.g., 3–7 medicines for daily chronic therapy) intended to reduce pill burden and improve adherence; it describes prescriptions being checked and released by its PharmD team using patented automation, followed by direct delivery to the patient typically within about 24 hours after receipt. OneFul also describes its technology platform as supporting individualized formulation informed by a patient’s genomic information paired with pharmaceutical pharmacogenomics (PGx) data.
This matters for patients managing chronic conditions that often require multiple pills and experience “pill fatigue,” missed doses, and complex day-to-day organization. OneFul presents its approach as simplifying medication routines by consolidating prescribed medicines into a single easy-to-take form while aiming to reduce adverse effects and improve effectiveness via individualized drug selection/dosing. The company’s SEC filings identify OneFul Health Inc. as the issuer behind the OneFul effort and include the company name, address, and that it operates the OneFul business at the referenced website domain.
delivered to your inbox.